If semaglutide hasn't delivered, that's information, not a dead end
Your provider will provide specific instructions on how to do your injections
Tirzepatide mimics the GLP-1 hormone and the GIP hormone
In October of last year, when the FDA removed Lillys tirzepatide from the shortage list, the OFA and Texas-based FarmaKeio Superior Custom Compounding filed a lawsuit, claiming that the regulators decision was based solely on the companys declaration that the shortage was over and calling the FDAs choice reckless and arbitrary." Two months ago, when the FDA removed Novos drugs from the shortage list and gave compounders a grace period of between 60 and 90 days to halt production of semaglutide, the OFA and FarmaKeio filed another lawsuit
[1] [3] Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar clinical effects
Family history of cardiovascular disease